Immunosurveillance for intracellular pathogens is primarily mediated by conventional TCR ␣ ␤ CD8 T lymphocytes that recognize pathogenderived oligopeptides presented by " classical " MHC class Ia molecules (the H-2K, D, and L molecules in the mouse). Yet, a sizeable number of H-2D distal genes in the Q, T, and M regions of the mouse MHC and the non -MHC-linked CD1 and MR1 genes encode ␤ 2 microglobulin ( ␤ 2 m) -associated class I glycoproteins. Compared with MHC class Ia molecules, these " nonclassical " class Ib molecules have limited polymorphism, low-level ubiquitous or tissue-specifi c expression, truncated cytoplasmic/transmembrane domains, and/or alternative splicing patterns ( 1 ) . Several class Ib molecules have been shown to mediate immunoregulatory as well as nonimmunological functions ( 2 -6 ) . CD8 T cells restricted by MHC class Ib molecules have also been implicated in microbial defense. In particular, the mouse class Ib molecules H2-M3, CD1d (and human CD1), and Qa-1 (and its human orthologue HLA-E) serve as TCR restriction elements for CD8 T cells that provide immunity against intracellular bacteria, including Listeria monocytogenes , Mycobacterium tuberculosis , and Salmonella typhimurium , respectively ( 7 -9 ) . H2-M3 preferentially presents N -formyl peptides, and CD1 presents mycobacterial lipid antigens to nonconventional T cells implicated in immunity to M. tuberculosis infection. Other than Qa-1 and HLA-E, which present the GroEL nonamer peptide from S. typhi , there are few examples of class Ib molecules that present " class Ia -like " peptides and none that serve as ligands for CD8 T cells that fi ght nonbacterial pathogens ( 1 ) .
Limited evidence suggests that class Ibrestricted CD8 T cells may also contribute to viral immunity. Early studies identifi ed a nonformylated peptide derived from the infl uenza virus hemagglutinin that induced an in vitro primary expansion of H2-M3 -restricted CD8 CTLs, but these CTLs were unable to kill infl uenza virus -infected cells ( 10, 11 ) . In addition, HLA-E -restricted TCR ␣ ␤ CD8 CTL cloned lines recognizing a nonamer peptide derived from the UL40 protein of human CMV have been previously described ( 12 ) . Recently, Braaten et al. demonstrated that ␤ 2 m-dependent TCR ␣ ␤ CD8 T cells in mice selectively lacking MHC class Ia molecules (K b Ϫ / Ϫ D b Ϫ / Ϫ mice) controlled chronic infection by rodent ␥ -herpesvirus 68, although the class Ib -restricting molecule and viral epitope remain to be identifi ed ( 13 ) .
Polyomaviruses are highly prevalent vertebrate pathogens that generally cause a self-limited acute infection followed by long-term asymptomatic persistent infection in their natural host reservoir ( 14 ) . In the immunosuppressed population, human polyomaviruses JC and BK can reactivate with severely debilitating consequences, including a typically fatal central nervous system demyelinating disease and allograft nephropathy, respectively ( 15, 16 ) . Recently, two new human polyomaviruses have been identifi ed in respiratory tract infections, and another has been associated with the cutaneous malignancy Merkel cell carcinoma ( 17 -19 ) . Mouse polyomavirus (PyV) establishes low-level systemic persistent infection and causes tumors in immunocompromised mice and neonatally infected mice of certain inbred strains ( 20 ) . The ‫ف‬ 5-kb double-stranded PyV genome encodes only six proteins, three nonstructural proteins (small T, middle T [MT], and large T [LT] antigens) and three capsid proteins (VP1, VP2, and VP3). Interestingly, only peptides derived from the T antigens have been defi ned as epitopes for MHC class Iarestricted PyV-specifi c CD8 T cells ( 14, 21 ) .
In this study, we investigated whether PyV infection elicits virus-specifi c CD8 T cells restricted by MHC class Ib molecules. We previously showed that ␤ 2 m Ϫ / Ϫ mice ineffi ciently control PyV infection, as indicated by the realization of this virus ' s oncogenic potential ( 22 ) . Unexpectedly, K b Ϫ / Ϫ D b Ϫ / Ϫ mice are highly resistant to tumor formation and effi ciently control PyV infection, implicating MHC class Ia -independent CD8 T cells in surveillance for PyV-infected cells. We identifi ed the ligand for the dominant PyV-specifi c CD8 T cell response in K b Ϫ / Ϫ D b Ϫ / Ϫ mice as a VP2-derived nonameric peptide presented by Q9, a member of the Qa-2 family of Q region -encoded MHC class Ib molecules. Importantly, PyV infection also elicits Q9-restricted VP2-specifi c CD8 T cells in wild-type mice. Our fi ndings provide the fi rst formal demonstration of an antigen-specifi c class Ib -restricted CD8 T cell response that confers immunity to a viral infection.
RESULTS

MHC class Ia -defi cient mice control PyV infection
In contrast to ␤ 2 m Ϫ / Ϫ mice, which are both MHC class Iaand class Ib -defi cient and highly susceptible to PyV tumorigenesis ( 22 ) , we observed that PyV-infected MHC class Ia -defi cient K b Ϫ / Ϫ D b Ϫ / Ϫ mice retain the resistance to PyV-used TAP2-defi cient, MHC class Ia -negative B78H1 lines stably transfected with TAP2 and Q8 (H1Q8TAP.11), TAP2 and Q9 (H1Q9TAP11), or TAP2 and empty vector (H1TAP.11) as target cells in cytotoxicity assays ( 26 ) . As shown in Fig. 2 D , only VP2.139 peptide -loaded cells expressing Q9 were recognized by these CD8 T cell clones. Collectively, these results defi ne Q9-VP2.139 as the ligand for TCRs expressed by the PyV-specifi c CD8 T cell clone lines isolated from
Visualization of Q9-VP2.139 -specifi c CD8 T cells in K b
We constructed Q9 tetramers complexed to the VP2.139 peptide to monitor the evolution of these novel antigen-specifi c CD8 T cells through the course of PyV infection. To confi rm the specifi city of the Q9-VP2.139 tetramers, we determined that tetramer + CD8 T cells were readily detectable in spleens of K b Ϫ / Ϫ D b Ϫ / Ϫ mice infected by wild-type PyV, but not in uninfected mice ( Fig. 3 A ) . Moreover, the Q9-VP2.139 tetramer did not stain CD8 T cells in mice infected by a mutant having a histidine at P7 within the VP2 aa sequence 133 -151 ( Table II ) , only 139 -147 of the VP2 PyV capsid protein (VP2.139) stimulated intracellular IFN-␥ production by all of the K b Ϫ / Ϫ D b Ϫ / Ϫ mouse -derived CD8 T cell clones ( Fig. 2 C ) . Single residue truncations of the VP2.139 peptide at the carboxy or amino terminus resulted in peptides that did not stimulate any of the clones, indicating that aa 139 -147 of VP2 represent the minimum Qa-2 -restricted epitope (unpublished data). Interestingly, the carboxy terminus of VP2.139 is occupied by tryptophan, a residue not detected at this position among endogenous peptides eluted from Qa-2 molecules ( 23 ); however, the Qa-2 F pocket is relatively spacious and can accommodate large side chains ( 24 ) .
The Qa-2 family is composed of several members, of which Q9 is among the most thoroughly characterized mouse class Ib proteins. Q9 and another Qa-2 family member, Q8, share largely overlapping peptide-binding motifs, despite having > 20 aa diff erences in the ␣ 1 and ␣ 2 domains ( 25 ) . To determine whether Q8 and/or Q9 present the VP2.139 epitope to the K b Ϫ / Ϫ D b Ϫ / Ϫ PyV-specifi c CD8 T cell clones, we Chronic encounter by cognate antigen typically directs MHC class Ia -restricted CD8 T cells toward an eff ector differentiation state having curtailed eff ector competency. To determine whether persistent PyV infection similarly aff ected this antiviral CD8 T cell response in K b Ϫ / Ϫ D b Ϫ / Ϫ mice, we phenotypically and functionally characterized VP2.139-specifi c CD8 T cells during their expansion (day 35 p.i.) and long-term maintenance (day 178 p.i.) phases. At day 35 p.i., Q9-VP2.139 tetramer + CD8 T cells displayed an overall eff ector-like phenotype (CD44 hi , CD94/NKG2 hi , and CD122 lo ; unpublished data), but with a mixed CD43 (clone 1B11 epitope), CD62L-selectin, and IL-7R ␣ (CD127) expression pattern, and elevated expression of killer cell lectin-like receptor subfamily G, member 1 (KLRG1), a marker of short-lived eff ector CD8 T cells ( Fig. 3 C ) ( 28, 29 ) . By day 178 p.i., however, the VP2.139-specifi c PyV in which the Q9-anchoring histidine in the VP2.139 epitope was replaced by alanine (designated A2.H145A). Direct ex vivo Q9-VP2.139 tetramer staining showed that PyVinfected K b Ϫ / Ϫ D b Ϫ / Ϫ mice did not generate a detectable antigen-specifi c CD8 T cell response in either spleen or lung until day 8 of infection, at which point VP2.139 epitope -specifi c CD8 T cells steadily increased in both frequency and magnitude into persistent infection ( Fig. 3 B ) . Notably, by 80 d p.i., VP2.139-specifi c CD8 T cells represented nearly 80% of CD8 T cells in the lung and blood (unpublished data), and 40% of splenic CD8 T cells. This T cell response profi le diff ers considerably from that of MHC class Ia -restricted anti-PyV CD8 T cell responses, where tetramer + CD8 T cells are typically detected by 5 d p.i., peak in magnitude by 8 d p.i., and then quickly contract to a lower long-term steady-state level ( 14, 27 ) . Table I . Overlapping VP2 peptides used to map the Qa-2 -restricted PyV-specifi c T cell epitope Peptide no. ( Fig. 4 A ) . Interestingly, a fraction of the VP2.139-specifi c CD8 T cells acquired the ability to coproduce IFN-␥ and TNF-␣ at a late time point, when persistent infection viral loads had fallen ( Fig. 1 A and Fig. 4 B ) . To assay antigen-specifi c cytotoxic activity in vivo, CD8 T cells assumed an unusual phenotype overlapping both eff ector and memory phenotypic profi les, consistent with repetitive antigenic stimulation of memory CD8 T cells ( 30, 31 ) . Although nearly all of the maintenance-phase Q9-VP2.139 tetramer + CD8 T cells were CD62L lo , they had reduced expression of CD27 and CD43, and increased levels of surface IL-7R ␣ . This CD27 lo CD43 lo CD127 hi profi le has been recently ascribed to CD8 T cells having strong recall response capability ( 32 ) . Notably, VP2.139-specifi c CD8 T cells at days 35 and 178 p.i. did not express the inhibitory programmed death 1 receptor (unpublished data), which is often present on the surface of functionally impaired MHC Table II . Peptides fi tting the Q9 peptide-binding motif VP2 sequence Fig. 4 C ) ; the longer assay timeframe may enable colocalization of target cells with the low numbers of VP2.139-specifi c CD8 T cells, which, given their cytokine eff ector dysfunction, may also suff er reduced cytotoxic eff ector capability.
VP2.139-specifi c CD8 T cells confer antiviral immunity
We used two approaches to directly determine whether VP2.139-specifi c CD8 T cells operated to protect the host from viral infection. We fi rst asked whether K b Ϫ / Ϫ D b Ϫ / Ϫ mice were able to control infection by the VP2.139 epitope null mutant PyV, A2.H145A. As shown in Fig. 5 A , at day 5 p.i. no diff erences were seen in viral load between the parental and mutant viruses in multiple organs (spleen and kidney are shown). Thus, this single mutation at aa 145 in VP2 did not alter the capacity of PyV to replicate and disseminate in vivo at a time point preceding the emergence of a detectable CD8 T cell response ( 
mice that were simultaneously infected either by A2 or A2.H145A PyVs. On day 5 p.i., virus levels were significantly lower in recipients of the parental PyV than the VP2.139 epitope null mutant PyV ( Fig. 5 B ) . Collectively, these studies indicate that VP2.139-specifi c CD8 T cells mediate viral clear-
B6 mice generate Q9-VP2.139 -specifi c CD8 T cells
To determine whether PyV infection elicits Q9-restricted VP2.139-specifi c CD8 T cells in B6 mice, we initially used our standard inoculation dose of 10 6 PFU and monitored blood and spleen over the course of infection for CD8 T cells that bound Q9-VP2.139 tetramers. Under these conditions, we were unable to detect VP2.139-specifi c CD8 T cells (unpublished data). Based on our recent fi nding that antigennonspecifi c bystander infl ammation associated with PyV infection impairs the antiviral CD8 T cell response ( 33 ), we reduced the viral inoculation dose 1,000-fold. As shown in Fig. 6 A , Q9-VP2.139 tetramers now stained CD8 T cells in approximately one third of infected B6 mice at day 11 p.i., the ( Fig. 6 C ) . Coincident with this functional defi cit, Q9-VP2.139 CD8 T cells express a higher level of surface KLRG1 and a lower level of CD127 compared with D b -LT359 CD8 T cells ( Fig. 6 D ) . Thus, although MHC class Ib -restricted antiviral CD8 T cells are indeed recruited into the PyV-specifi c CD8 T cell response in acutely infected B6 mice, these T cells appear to be more terminally diff erentiated at this time point than the MHC class Ia -restricted antiviral CD8 T cells.
DISCUSSION
In this study, we identifi ed a novel MHC class Ib peptide ligand for virus-specifi c CD8 T cells and demonstrated that these antiviral T cells confer protection against infection. We found that the MHC class Ia -defi cient K b Ϫ / Ϫ D b Ϫ / Ϫ mice efficiently control infection by PyV and mount an antiviral CD8 T cell response that is predominantly directed toward a viral capsid -derived nonamer peptide bound to Q9, a member of the Qa-2 family of MHC class Ib molecules. Of the ␤ 2 massociated MHC class I products encoded in the Qa-2 locus, only Q9-restricted T cell responses have been previously shown to contribute to host immunity. An early report showed that expression of Q9 correlated with resistance to mouse cysticercosis ( 34 ) . More recently, it has been demonstrated that immunization by Q9-expressing tumor cells elicits Q9-restricted CTLs, which are capable of cross-protecting against histologically disparate Q9 + tumors ( 35, 36 ) . A role for Q9-restricted CD8 T cells in antiviral immunity has been postulated and is supported by evidence that synthetic peptides from several viral proteins are capable of binding to Q9 molecules ( 37 ) . To our knowledge, however, the data presented in this paper represent the fi rst identifi cation of a Qa-2 -restricted T cell epitope and the fi rst description of a MHC class Ib -restricted virus-specifi c CD8 T cell response in vivo.
An unusual feature of the Q9-restricted CD8 T cell response in K b Ϫ / Ϫ D b Ϫ / Ϫ mice is its steady accumulation during encoded by an early region transcript and are expressed by both productively and nonproductively infected cells. In contrast, the VP2.139 epitope is derived from a late-region viral capsid protein, whose synthesis is limited to productively infected cells. One possibility is that the Q9-VP2.139 CD8 T cell response may be at a disadvantage compared with MHC class Iarestricted LT/MT-specifi c CD8 T cell responses both in timing of expression of the VP2 protein during the PyV lifecycle and the number and range of cells presenting the VP2.139 epitope. Alternatively, Q9 cell-surface expression, like MHC class Ia molecules, is up-regulated by certain infl ammatory cytokines, such as IFN-␥ ( 46 ), and may thus be subject to modulation in the context of virus infection. Thus, viral capsid -specifi c CD8 T cells may preferentially operate during persistent infection to contain pockets of active viral infection, a possibility supported by evidence that the VP2.139-specifi c CD8 T cells from persistently infected mice control PyV in acutely infected recipients ( Fig. 5 B ) .
The inability of Q9 to effi ciently use CD8 coreceptors ( 47 ) may contribute to the reduced magnitude and eff ector capability of CD8 T cells restricted by this class Ib molecule. Mice transgenic for a recombinant MHC class Ia molecule whose ␣ 3 domain was exchanged for that of Q7 (which is identical to Q9) ( 48 ) show profound ineffi ciency in the selection of MHC class I alloreactive CD8 CTLs. The recently solved Q9 crystal structure reveals that the AB loop of Q9 ' s ␣ 3 domain points away from where it would normally bind CD8 in MHC class Ia molecules ( 24 ) . A small pool of VP2.139-specifi c naive T cells may explain the delay in expansion of PyV-specifi c CD8 T cells in K b Ϫ / Ϫ D b Ϫ / Ϫ mice. Weak CD8 engagement may also raise T cell activation thresholds for Q9-restricted T cells, requiring elevated epitope densities to achieve full eff ector potential and possibly altering the diff erentiation of T cells recruited into the antiviral response ( 49, 50 ) . In this connection, it is interesting to note that CD8 ␣ Ϫ / Ϫ mice mount a delayed, cytokine eff ector function -handicapped, H-2D b -restricted PyV-specifi c T cell response ( 40 ) .
The central question is to what extent MHC class Ib -restricted T cells contribute to viral immunity. MHC class Ibrestricted CD8 T cells may provide a contingency for the host against viral immune evasion. For example, human CMV encodes a mimic MHC class Ia leader peptide, UL40, which binds to HLA-E and engages inhibitory CD94/NKG2A receptors on NK cells ( 51 ) . Yet, HLA-E/UL40 -specifi c CD8 T cells with cytokine and cytotoxic eff ector capabilities have been isolated from CMV-seropositive individuals ( 12 ) . From a general perspective, MHC class Ib -restricted CD8 T cells expand epitope diversity of the antiviral immune response and protect against immune selection of epitope-escape viral variants. More specifi cally, because the dominant antiviral CD8 T cell response is directed toward MHC class Ia -presented epitopes, MHC class Ib -restricted T cells may assume importance as a failsafe antiviral defense strategy. From the surface phenotype of the VP2.139-specifi c CD8 T cells, which suggests recall-competent eff ector/eff ector -memory cells ( Fig. 3 C ) , it is tempting to speculate that MHC class Ib -restricted would not encounter immunodomination by MHC class Iarestricted T cells, as described for the H2-M3 -restricted memory CD8 T cell response to L. monocytogenes ( 44 ) . Thus, in K b Ϫ / Ϫ D b Ϫ / Ϫ mice, VP2.139-specifi c CD8 T cells would have unfettered access to viral epitope -expressing cells, as well as to mitogenic and survival cytokines. A related factor may be that Q9 surface expression (and presumably Q9 epitope density) is higher in K b Ϫ / Ϫ D b Ϫ / Ϫ mice than in MHC class Ia -suffi cient mice ( 45 ) , possibly because of a lack of competition for ␤ 2 m and MHC class I chaperone molecules. It is also worth noting that to date we have identifi ed anti-PyV CD8 T cell epitopes only from the nonstructural LTs and MTs ( 14, 21 ), which are Cell isolation and fl ow cytometry. Single-cell suspensions were made of popliteal lymph node cells and RBC-lysed spleens. For lung lymphocyte isolation, mice were perfused with PBS containing 100 U/ml heparin, and lungs were digested in vitro by collagenase and centrifuged on Percoll step gradients, as previously described ( 59 ) . Antibodies to CD8 ␣ , CD43, CD44, CD62L, and NKG2A/C/E (clone 20d5) were purchased from BD Biosciences and used according to the manufacturer ' s specifi cations. Anti-CD27, anti-CD127, and anti -programmed death 1 were purchased from eBioscience. Anti-KLRG1 was purchased from SouthernBiotech. Q9-VP2.139 tetramers were constructed by the National Institutes of Health Tetramer Core Facility at Emory University using cloned full-length Q9 cDNA ( 60 ) . Tetramer staining was performed, along with antibody surface staining for 35 min at room temperature in PBS containing 2% FBS and 0.1% sodium azide. Samples were acquired on a FACSCalibur (BD Biosciences), and data were analyzed using FlowJo software (Tree Star, Inc.).
IFN-␥ ELISPOT assay.
Single-cell ELISPOT assays were performed as previously described ( 17 ) . In brief, 96-well fi ltration plates (Millipore) were coated overnight with anti -IFN-␥ (R4-6A2; BD Biosciences). 2 wk after stimulation by infected, irradiated Intracellular antibody staining. Cells were stimulated directly ex vivo with 1 μ M VP2.139 peptide for 5 h in the presence of brefeldin A, and were then stained for surface CD8 and intracellular cytokines, as previously described ( 14 ) . For assays using CD8 T cell clones, the clones were labeled with CFSE to distinguish them from splenic stimulator cells. mAbs to IFN-␥ and TNF-␣ were purchased from BD Biosciences. For granzyme B staining, spleen cells were surface stained directly ex vivo with anti-CD8 ␣ and Q9-VP2.139 tetramers, permeabilized using the Cytofi x/Cytoperm kit (BD Biosciences), and stained with anti -human granzyme B or the isotype control antibody (Invitrogen).
In vivo CD8 T cell depletion. CD8 ␤ mAb (clone H35; provided by P. Allen, Washington University, St. Louis, MO) ( 61 ) was prepared in fl asks (INTEGRA Celline CL1000; Integra Biosciences) using defi ned IgG-free medium (Invitrogen), according to the manufacturer ' s instructions. 1 mg anti-CD8 ␤ or ChromPure rat IgG (Jackson ImmunoResearch Laboratories) was administered i.p. on days Ϫ 3, Ϫ 1, and +1 from the day of PyV infection, with antibodies given every 5 d up to day 30 p.i. No CD8 ␣ -expressing CD3 + T cells were detected in spleens of CD8 ␤ mAb -treated mice at day 35 p.i. (unpublished data).
In vivo cytotoxicity assay. RBC-lysed, single-cell spleen suspensions from naive K b Ϫ / Ϫ D b Ϫ / Ϫ mice were pulsed at 10 7 cells/ml with 10 μ M VP2.139 peptide or without peptide in DMEM containing 10% FBS for 30 min at 37 ° C. Each cell population was stained at 10 7 cells/ml in HBSS (Invitrogen) with 2 mM CellTrace Far Red DDAO-SE (Invitrogen) at T cells may be play a substantial role in limiting persistent viral infection.
Because MHC class Ib molecules have few polymorphisms, identifi cation of MHC class Ib -restricted epitopes would off er much more comprehensive coverage across a population for peptide-based CD8 T cell -mediated immunotherapy than can be achieved by immunization using MHC class Ia -restricted peptides. Although Q9 is a mouse-only MHC class Ib molecule, HLA-G has been proposed to constitute its functional human homologue ( 52 ) . It is also notable that PyV is unique among avian and mammalian polyomaviruses in possessing a VP2.139 sequence available for binding to Q9 ( 53 ) . This apparent example of host -pathogen coevolution lends additional support toward uncovering MHC class Ib -restricted antiviral CD8 T cell responses in humans, with the prospect of developing seemingly " non -MHC-restricted " epitope-based vaccinations for viral infections.
MATERIALS AND METHODS
Mice. C57BL/6NCr (B6) female mice were purchased from the Frederick Cancer Research and Development Center of the National Cancer Institute. ( 45 ) Cell lines. The derivation and maintenance of the B78H1 transfectants expressing TAP2 (designated H1TAP.11), TAP2 and Q8 (designated H1Q8TAP.11), or TAP2 and Q9 (designated H1Q9TAP.11) have been previously described ( 25 ) . Quantitation of PyV genomes. DNA isolation and Taqman-based realtime PCR were performed as previously described ( 14 ) . PyV DNA quantity is expressed in genome copies per milligram of tissue and is calculated based on a standard curve of known PyV genome copy numbers versus threshold cycle of detection. The detection limit with this assay is 10 copies of genomic viral DNA.
Synthetic peptides. VP2.133-141, VP2.139-147, and VP2.143-151 peptides ( Table II ) and LT359-368Abu peptide ( 33 ) were synthesized by the solidphase method using F-moc chemistries. Peptide stocks were solubilized in water or DMSO and stored at -20 ° C. Peptides were diluted in assay medium immediately before use. The MT and LT peptide libraries, consisting of 17mer peptides overlapping by 12 aa, were prepared as PepSets by Chiron and were provided by J. Altman (Emory Vaccine Center, Atlanta, GA); the VP1 and VP2 peptide libraries, consisting of 15mer peptides overlapping by 10 aa, were room temperature for 10 min, with labeling stopped by addition of an equal volume of FBS for 1 min. Each cell population was labeled with a diff erent concentration of CFSE (1 or 0.1 mM) at 2 × 10 7 cells/ml in HBSS, with labeling stopped by addition of an equal volume of FBS for 1 min. 5 × 10 6 no-peptide and VP2.139 peptide -pulsed cells were mixed together and injected i.v. into infected and uninfected K b Ϫ / Ϫ D b Ϫ / Ϫ mice. Specifi c elimination of donor cells was determined at 4 and 12 h after transfer, as previously described ( 62 ) . 51 Cr release assay. Adherent H1TAP.11, H1Q8TAP.11, and H1Q9TAP.11 target cells were radiolabeled with 150 -200 μ Ci of Na 2 51 CrO 4 (400 -1,200 Ci/g; PerkinElmer) and pulsed with 10 μ M VP2.139 peptide at 37 ° C for 1.5 h, as described previously ( 58 ) . Target cells were aliquotted at 5,000 cells per well into U-bottom 96-well microtiter plates and co-cultured at 37 ° C for 5 h with PyV-specifi c CD8 T cell cloned lines at the eff ector/target (E:T) ratios indicated in the fi gures in quadruplicate wells, and the percentage of specifi c 51 Cr release was determined as previously described ( 58 ) .
Statistical analysis. Statistics were performed using statistical software (Prism; GraphPad Software, Inc.). All analyses were unpaired Student ' s t tests. P ≤ 0.05 was considered statistically signifi cant.
